1. Fulfilment reliability and capacity · 20%2. Continuity and dependency risk · 15%3. Total cost and patient affordability · 20%4. State and cohort operational readiness · 10%5. Workflow, integration and reporting · 12%6. Patient service and nonclinical exception handling · 8%7. Contract flexibility and financial exposure · 10%8. Implementation and accountable governance · 5%
Weights total: 100 / 100. A clinic may change the weights before opening proposals—for example, increasing integration weight during platform consolidation. Record the rationale, retain a 100-point total and apply the same version to every candidate. Do not change weights after seeing which supplier wins.
Criterion / evidence
Weight
Mandatory gates · Any hold or fail prevents ranking
G1 / Counterparty, facility and destination permissionsEvidence to review
Match legal names, addresses and relevant licence identifiers; verify applicable home-state and destination-state permissions; identify subcontracted dispensing locations.
A trading name substitutes for the actual pharmacy; required permissions cannot be verified; an undisclosed facility performs fulfilment.
Owner: Compliance and counsel
Gate
G2 / Product and supply-route eligibilityEvidence to review
Identify approved or compounded status, exact preparation, intended use and statutory pathway. For proposed compounding, obtain preparation-specific clinical and legal review.
Reliance only on patient-specific prescribing, an added ingredient, FDA registration, or a historic shortage.
Owner: Medical director and counsel
Gate
G3 / Provenance and traceabilityEvidence to review
Identify the source and distribution chain; obtain relevant transaction records and an allocation of applicable DSCSA responsibilities; test lot identification and quarantine procedures.
Unexplained intermediaries, mismatched labels or invoices, or inability to identify affected supply.
Owner: Pharmacy/quality lead and compliance
Gate
G4 / Quality, storage and recall readinessEvidence to review
Review facility-specific inspection and remediation records, applicable quality documentation, product-specific storage controls, excursion handling and recall procedures. For eligible compounded preparations, request formulation-relevant testing and dating support.
Material quality concerns remain unresolved; the supplier will not provide sufficient assurance; storage or recall responsibilities are unassigned.
Owner: Qualified quality reviewer and medical director
Gate
G5 / Medication-use safety and clinical independenceEvidence to review
Approve label examples, concentration/device instructions, pharmacist access, complaint and adverse-event escalation, and product-change controls. Prescribing decisions remain with clinicians.
Instructions cannot be reconciled; commercial staff determine treatment changes; clinical escalation has no accountable owner.
Owner: Medical director and pharmacy lead
Gate
G6 / Privacy and securityEvidence to review
Map data flows and legal roles; assess access controls, subcontractors, incident handling and required agreements.
Unapproved data uses, material security gaps, or missing agreements where required.
Owner: Privacy counsel and security lead
Gate
G7 / Financial-arrangement complianceEvidence to review
Review fees, rebates, ownership links, marketing support and referral-related remuneration under the applicable federal and state framework.
The commercial model depends on payments counsel cannot approve or undisclosed financial interests.
Owner: Counsel and CFO
Gate
Weighted criteria · Rating is capped by the evidence level
1. Fulfilment reliability and capacityRating anchors
Weak: Shipping promises without complete order-level evidence; backlog and cancellations omitted.
Acceptable: Defined service windows, reconciled historical data and written capacity commitments support forecast demand.
Excellent: Matched-cohort performance is independently checked across multiple periods; peak-load and exception tests meet the agreed stretch targets.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
2. Continuity and dependency riskRating anchors
Weak: A second supplier name is offered without confirmed eligibility, acceptance or capacity.
Acceptable: Approved fallback routes, current acceptance confirmations and a documented interruption playbook.
Excellent: Tested fallback handles the agreed disruption scenario; shared facilities, distributors, software and other common dependencies are mapped.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
3. Total cost and patient affordabilityRating anchors
Weak: Introductory price only; payer responsibilities, later fills or fees are unclear.
Acceptable: Matched full-period model separates clinic, patient and insurer expenditure and stays within approved limits.
Excellent: Quotes reconcile to invoices or test transactions; adverse scenarios remain within buyer-approved limits, with transparent repricing and replacement treatment.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
4. State and cohort operational readinessRating anchors
Weak: Licensed coverage is marketed as operational readiness without product acceptance or workflow testing.
Acceptable: Every mandatory state and patient cohort has a named route, acceptance confirmation and launch owner.
Excellent: State/cohort tests demonstrate onboarding, delivery, payment and support; expansion dependencies have dated completion evidence.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
5. Workflow, integration and reportingRating anchors
Weak: Status ends at prescription submission; staff chase orders manually.
Acceptable: Receipt, clarification, payment, dispensing, delivery and cancellation statuses are accessible; exports and exception owners are defined.
Excellent: Buyer-tested reconciliation, duplicate protection, outage recovery and usable exports work across all material routes.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
6. Patient service and nonclinical exception handlingRating anchors
Weak: Patients are passed between clinic and pharmacy; charges and next steps are unclear.
Acceptable: Named ownership, understandable communications and support targets cover routine failures.
Excellent: Measured service consistently meets stretch targets; language/accessibility needs and difficult scenarios are tested.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
7. Contract flexibility and financial exposureRating anchors
Weak: Large prepayments, unclear refunds, automatic lock-in or weak exit assistance.
Acceptable: Approved exposure limits, defined remedies, price-change treatment and transition obligations.
Excellent: Executable terms materially limit stranded commitments; exit, reconciliation and transition procedures are tested and commercially usable.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
8. Implementation and accountable governanceRating anchors
Weak: Launch depends on informal cooperation and an optimistic start date.
Acceptable: Named owners, dependency plan, training, pilot acceptance and review cadence.
Excellent: A controlled rehearsal and pilot meet acceptance criteria; rollback and evidence-refresh responsibilities are demonstrated.
Effective rating: — / 5
Effective rating: — / 5
Effective rating: — / 5
Candidate A— / 1000Below 70 / 70–79 / 80–100
Documented or verified evidence: 0%
HOLD — unranked
Resolve every gate before a live pilot or supply commitment.
Candidate B— / 1000Below 70 / 70–79 / 80–100
Documented or verified evidence: 0%
HOLD — unranked
Resolve every gate before a live pilot or supply commitment.
Candidate C— / 1000Below 70 / 70–79 / 80–100
Documented or verified evidence: 0%
HOLD — unranked
Resolve every gate before a live pilot or supply commitment.
A HOLD is not an allegation of wrongdoing. A FAIL applies to the assessed arrangement and may be reconsidered after a documented remedy. Neither receives a commercial ranking while unresolved. Evidence coverage is reported separately; it does not multiply the total.
Answers stay in this session unless you choose to save. No account needed.